- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- Ibrutinib, Rituximab, Ifosfamide, Carboplatin, Etoposide, Vincristine, Idarubicin, Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 14 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1873–1896
of 5,351
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer, Cervical Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Lung Cancer, Prostate Cancer
- Interventions
- Physical Activity Promotion Intervention
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
- Interventions
- BMS-986177, Placebo, Clopidogrel, Aspirin
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Glendale, California • Long Beach, California + 51 more
- Conditions
- Relapsed/Refractory Aggressive B-cell Lymphomas
- Interventions
- MEDI-551 12 mg/kg, MEDI0680 2.5 mg/kg, MEDI0680 10 mg/kg
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • St Louis, Missouri + 3 more
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- Not listed
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Whittier, California • Miami, Florida + 8 more
- Conditions
- Colorectal Cancer
- Interventions
- FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 121
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 100 more
- Conditions
- Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
- Interventions
- Not listed
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
- Conditions
- Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Community Acquired Respiratory Disease Syndrome
- Interventions
- Inactive Substance, Methylprednisolone
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Loma Linda, California • Long Beach, California + 26 more
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
- Interventions
- Alpelisib, Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Computed Tomography, Echocardiography Test, Fluorouracil, Fulvestrant, Ipatasertib, Leucovorin, Magnetic Resonance Imaging, Multigated Acquisition Scan, Mutation Carrier Screening, Neratinib Maleate, Nilotinib Hydrochloride Monohydrate, Olaparib, Oxaliplatin, Paclitaxel, Palbociclib, Panitumumab, Positron Emission Tomography, Selumetinib Sulfate, Sotorasib
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 480
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 355 more
- Conditions
- Hemophilia A With Inhibitors
- Interventions
- Factor VIII concentrates, Low-dose treatment, High-dose treatment
- Drug · Other
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- Up to 7 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Duarte, California • Orange, California + 31 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 40
- States / cities
- Downy, California • Fountain Valley, California • Fullerton, California + 37 more
- Conditions
- Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2033
- U.S. locations
- 763
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more
- Conditions
- Obesity
- Interventions
- Transoral Suturing, Sham Endoscopy
- Device · Other
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Baltimore, Maryland • Boston, Massachusetts + 7 more
- Conditions
- Herpes Labialis
- Interventions
- NB-001
- Drug
- Lead sponsor
- NanoBio Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • Anaheim, California • Westlake Village, California + 23 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Bevacizumab and Temozolomide
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol
- Drug
- Lead sponsor
- UCB Celltech
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 21 more
- Conditions
- Multiple Sclerosis
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 56
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 52 more
- Conditions
- Generalized Myasthenia Gravis, Myasthenia Gravis
- Interventions
- ALXN2050, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
- Conditions
- Hearing Loss, Sensorineural, Noise Induced Hearing Loss, Sudden Hearing Loss
- Interventions
- FX-322, Placebo
- Drug
- Lead sponsor
- Frequency Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 26
- States / cities
- Tucson, Arizona • Fresno, California • Torrance, California + 23 more
- Conditions
- Tachyarrhythmias, Heart Failure, Ventricular Dysfunction
- Interventions
- Protecta VR-ICD, Protecta DR-ICD or CRT-D
- Device
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Fort Smith, Arkansas + 26 more
- Conditions
- Pain, Postoperative
- Interventions
- Percutaneous auricular neurostimulation, Sham percutaneous auricular neurostimulation
- Device
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Pressure Ulcers, Spinal Cord Injuries
- Interventions
- Self Management (SM), Motivational Interviewing (MI), Education (ED)
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 5
- States / cities
- Long Beach, California • Augusta, Georgia • Hines, Illinois + 2 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- afatinib, placebo
- Drug · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 272
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Fort Collins, Colorado + 186 more